ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Decrease in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 197,000 shares, a decline of 24.7% from the March 15th total of 261,600 shares. Based on an average trading volume of 137,600 shares, the short-interest ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research reports. HC Wainwright upped their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $80.00.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Muthusamy Shanmugam sold 9,784 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $55.30, for a total transaction of $541,055.20. Following the completion of the transaction, the chief operating officer now owns 907,836 shares of the company’s stock, valued at approximately $50,203,330.80. The disclosure for this sale can be found here. Insiders sold 143,286 shares of company stock worth $9,274,370 in the last 90 days. Corporate insiders own 28.50% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ANIP. Swiss National Bank grew its stake in ANI Pharmaceuticals by 7.1% in the 1st quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $759,000 after acquiring an additional 1,800 shares during the last quarter. Citigroup Inc. boosted its stake in shares of ANI Pharmaceuticals by 44.9% during the 1st quarter. Citigroup Inc. now owns 12,516 shares of the specialty pharmaceutical company’s stock worth $352,000 after purchasing an additional 3,881 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 15.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,828 shares of the specialty pharmaceutical company’s stock worth $108,000 after purchasing an additional 512 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of ANI Pharmaceuticals by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 5,858 shares of the specialty pharmaceutical company’s stock worth $165,000 after purchasing an additional 2,127 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of ANI Pharmaceuticals by 4.4% during the 1st quarter. Rhumbline Advisers now owns 25,916 shares of the specialty pharmaceutical company’s stock worth $728,000 after purchasing an additional 1,096 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded down $1.23 on Friday, reaching $66.88. 94,984 shares of the company were exchanged, compared to its average volume of 163,385. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals has a 1-year low of $36.99 and a 1-year high of $70.81. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of 79.62 and a beta of 0.79. The company has a 50-day moving average of $64.03 and a 200-day moving average of $58.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. Equities analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.